SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

The Trade Desk is trending as its CEO made a significant insider stock purchase, signaling strong confidence, while rumors of a potential partnership with OpenAI to sell ads are igniting community speculation about a major growth catalyst for the recently oversold ad-tech stock.

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil is experiencing extreme volatility and massive trading volume as escalating Middle East tensions and concerns over oil supply routes drive crude prices higher. The community is actively debating the stock's short squeeze potential, with bullish traders eyeing significant upside while others caution about profit-taking and its recent offering price.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating US-Iran tensions and concerns over the critical Strait of Hormuz are driving USO, with community debate sharply divided between expectations of prolonged supply disruptions and significant oil price increases versus anticipation of a rapid de-escalation and market interventions.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy Corp Ltd ($INDO) is trending amidst sharply rising crude oil prices and escalating geopolitical tensions threatening global oil supply, leading the community to anticipate a significant short squeeze. Many investors are drawing parallels to its explosive 2022 run, eagerly awaiting drilling updates as they navigate concerns about market manipulation and potential dilution.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending following a significant stock drop after releasing Phase 2 data for its HLP004 GAD treatment, sparking community debate over the trial's mixed efficacy signals and whether the market is overreacting to what the company frames as clinically meaningful results.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending following a strong earnings report that exceeded expectations and significantly raised future guidance, fueled by robust demand for its AI chips and a new partnership with OpenAI. The company's optimistic forecast for AI revenue is sparking intense discussion, with many anticipating continued growth, while some express caution about valuation and broader market conditions affecting the post-earnings momentum.

Palladyne AI Corp. engages in the design, development, and manufacture of industrial robotic systems that augment human performance by combining human intelligence, instinct, and judgment with the strength, endurance, and precision of machines to enhance employee safety and productivity. Its products include Palldyne IQ and Palladyne Pilot. The company was founded by Fraser M. Smith and Benjamin G. Wolff in 2015 and is headquartered in Salt Lake City, UT.

Palladyne AI Corp.

Palladyne AI Corp. is trending following its strong Q4 earnings report, reaffirming impressive future revenue growth guidance, and securing significant new defense contracts including missile propulsion systems and multi-domain swarming autonomy projects. The community is actively discussing the company's potential as a transformative player in defense AI and drone technology, with many likening it to early-stage industry leaders, further amplified by high short interest and expectations for a major upside move.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending following its Q4 earnings, which initially saw confusion over EPS figures before being clarified as an inline beat with robust revenue growth and record customer assets. The community is sharply divided, debating whether ongoing dilution concerns and historical stock performance outweigh these strong operational metrics, with many perceiving the stock as deeply undervalued in the fintech brokerage space.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

CorMedix is trending following its Q4 results and reaffirmed conservative 2026 guidance, which has ignited widespread community frustration over perceived management missteps and undervaluation. Despite the board authorizing a share buyback aimed at boosting value and potentially combating persistent short interest, investors are keenly awaiting upcoming Rezzayo data and new customer partnerships as crucial catalysts.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

United States Antimony Corp. is a top trending stock after securing a $27 million Department of War award for domestic antimony supply chain expansion, a critical mineral essential for national defense. This news, combined with escalating geopolitical tensions and a new tungsten deposit announcement, is driving strong community sentiment around the company's strategic market position and potential for short squeeze activity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints

Helus Pharma (Cybin) shares fall after Phase 2 anxiety drug results show symptom improvement, but pressure on the stock.read more...

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion PR Newswire NEW YORK, March 5, 2026 GAD...

FY2026 Earnings Forecast for Cybin Issued By HC Wainwright

Cybin Inc. (NASDAQ:HELP - Free Report) - Analysts at HC Wainwright dropped their FY2026 earnings per share estimates for shares of Cybin in a research note issued to investors on Monday, March 2nd...

<ul class="summary-bullets"><li>The clinical trial included 36 participants who continued taking existing medications for generalized anxiety disorder while receiving HLP004 injections.</li><li>Researchers administered two doses three weeks apart and monitored participants for 12 weeks.</li><li>Six months after treatment, about 67% of the combined study group met the criteria for a clinical response.</li></ul>Helus Pharma (HELP) announced encouraging early-stage clinical results for its experimental anxiety treatment HLP004 on Thursday, reporting notable symptom improvement among patients with moderate-to-severe generalized anxiety disorder.&nbsp;The clinical-stage drug developer said its Phase 2 signal detection trial showed statistically meaningful improvements when the therapy was used alongside standard antidepressant treatments.&nbsp;<h2 class="st-heading-2">Trial Demonstrates Significant Anxiety Reduction</h2>In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks.&nbsp;The clinical trial included 36 participants who continued taking existing medications for generalized anxiety disorder while receiving HLP004 injections. Researchers administered two doses, three weeks apart, and monitored participants for 12 weeks, with additional follow-up planned for up to 1 year.<a href="https://stocktwits.com/symbol/HELP">Helus Pharma stock</a> traded over 22% lower in Thursday’s remarket.&nbsp;<h2 class="st-heading-2">Long-Lasting Response Observed In Many Patients</h2>The company also reported sustained benefits beyond the initial treatment period. Six months after treatment, about 67% of the combined study group met the criteria for a clinical response, while 39% reached remission.Among those receiving the higher 20-milligram dose, 59% showed improvement and 32% achieved remission after six weeks. In the lower-dose group, about 30% of patients met response and remission benchmarks at the same time point.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>Despite the stock’s decline in the premarket session, retail sentiment on Stocktwits around the stock flipped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_03_05_083359_png_25a9744605.webp" alt="HELP’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Mar. 5, 2026 | Source: Stocktwits" width="925" height="96"><figcaption>HELP’s Sentiment Meter and Message Volume as of 08:30 a.m. ET on Mar. 5, 2026 | Source: Stocktwits</figcaption></figure>A Stocktwits user said they have bought the dip.&nbsp;<stembedurl>https://stocktwits.com/Jimbob3016/message/646658779</stembedurl>HELP stock has gained over 4% year-to-date.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/liquidia-stock-gains-premarket-on-q4-revenue-beat-investors-are-betting-on-yutrepia-growth/cZdQrwNRI33">Liquidia Stock Gains Premarket On Q4 Revenue Beat – Investors Are Betting On YUTREPIA Growth</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks. 

Equity

In the study, participants receiving a 20-milligram dose of HLP004 alongside standard-of-care treatment experienced an average drop of roughly 10.4 points on the Hamilton Anxiety Rating Scale after six weeks. 


Cybin (NASDAQ:HELP) Price Target Raised to $95.00 at HC Wainwright

HC Wainwright boosted their price target on Cybin from $55.00 to $95.00 and gave the company a "buy" rating in a report on Monday...

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments

Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments PR Newswire VANCOUVER, BC, Feb. 27...

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders

Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders PR Newswire VANCOUVER, BC, Feb. 26, 2026...

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity

Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity Next-Generation Psychiatric Therapies Target Massive $40B+ Market Opportunity PR Newswire NEW YORK, Feb. 24, 2026...

<ul class="summary-bullets"><li>The trial was evaluating the efficacy and safety of SPL026 and enrolled 34 participants who had experienced depression for an average of 10.5 years.</li><li>The reductions in depressive symptoms were observed as early as one week following dosing and were sustained at three months, the company said.&nbsp;</li><li>Helus Pharma, however, said that the company is not advancing intravenous SPL026 in its current form.</li></ul> Shares of Helus Pharma (HELP) rallied 11% on Tuesday after the company announced positive results from its mid-stage clinical trial evaluating its experimental therapy SPL026 in participants with moderate-to-severe major depressive disorder.The trial was to evaluate the efficacy and safety of SPL026, and enrolled 34 participants who had experienced depression for an average of 10.5 years.The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said.The reductions in depressive symptoms were observed as early as one week following dosing and were sustained at three months, with effects lasting up to six months in some participants, the company said. Further, no treatment-related serious adverse events were reported.<h2 class="st-heading-2">Executive Take Away</h2>“We have shown that a single dose of SPL026 is safe, effective and durable, with treatment effects comparable to other promising interventional treatments often requiring much longer treatment sessions.” said the study’s lead investigator Dr David Erritzoe.“Although such early trial results should always be interpreted with some caution, these data show the promise of DMT as a potentially more cost-effective treatment for clinical depression than related serotonergic agonists with longer psychoactive action due to the shorter dosing sessions,” they added<h2 class="st-heading-2">Other Pipeline Names</h2>Helus Pharma said that the company is not advancing intravenous SPL026 in its current form. However, the company will use the insights from the trial to inform its HLP004 development program. HLP004 is an experimental drug being studied in the treatment of generalized anxiety disorder. Data from a mid-stage study of HLP004 is expected in Q1 2026.The company is also developing experimental drug HLP003 as an adjunctive treatment for major depressive disorder.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around HELP stock stayed within the ‘extremely bullish’ territory while message volume stayed at ‘high’ levels.“Time to buy more,” a Stocktwits user wrote while raising optimism for the GAD study data raising prices.<stembedurl>https://www.stocktwits.com/brunoq14/message/645159567</stembedurl>Another user, however, expects the stock to pare the gains made on Tuesday through the week.<stembedurl>https://www.stocktwits.com/ChristopherMcC/message/645124808</stembedurl><a href="https://stocktwits.com/symbol/HELP">HELP stock</a> has dropped 27% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/krys-stock-rallies-on-upbeat-earnings-jefferies-ups-price-target/cZRWvWzR4HT">KRYS Stock Rallies On Upbeat Earnings: Jefferies Ups Price Target On Sustained Vyjuvek Optimism</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’

The study showed statistically significant and clinically meaningful reductions in depressive symptoms at two weeks in participants treated with SPL026 compared with placebo, the company said.

Cybin (NASDAQ:HELP) Announces Earnings Results

Cybin (NASDAQ:HELP - Get Free Report) posted its earnings results on Friday. The company reported ($0.72) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by...

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $COST earnings Thursday?

Stocktwits

Costco Wholesale Corp

Stocktwits Polls

The stock experienced a significant multi-percent drop post-Phase 2 HLP004 results, surprising many investors who viewed the data as positive.

Debate is swirling around the Phase 2 study's methodology, particularly the pooling of 20mg and 2mg doses which some believe invalidates efficacy claims.

Despite the sharp decline, numerous investors are "buying the dip" and adding to positions, betting on a rebound and the company's long-term potential supported by its cash runway.

Many users cite the common "sell the news" pattern in the biotech sector, comparing this stock's reaction to other psychedelic and CNS therapy companies.

The stock's ticker symbol "$HELP" is a popular topic, with many users finding dark humor in its appropriateness amidst the recent sharp price drop.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.78	--	--	N/A
Q3 '25	-$0.76	-$1.00	-31.58%	MISSED

HELP
Helus Pharma Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q3 '25

Historical Earnings

Latest HELP News

HELPHelus Pharma Inc.